Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• RAS-extracellular signal-regulated kinase (ERK) signaling is implicated in numerous tumor types.
• Current anticancer drug development often targets kinase catalytic activity within this pathway.
• Existing therapies face challenges with toxicity and drug resistance.

Purpose of the Study:

• To review recent advancements in targeting RAS-ERK signaling.
• To explore novel therapeutic strategies focusing on protein-protein interactions (PPIs).
• To highlight the potential of PPI inhibitors in cancer treatment.

Main Methods:

• Literature review of preclinical studies.
• Analysis of research on targeting RAS-ERK pathway components.
• Summarization of emerging therapeutic approaches.

Main Results:

• Targeting protein-protein interactions (PPIs) in the RAS-ERK pathway shows promise.
• Preclinical models demonstrate the efficacy of PPI-focused strategies.
• Alternative approaches to kinase inhibition are emerging.

Conclusions:

• Targeting PPIs in the RAS-ERK pathway represents a viable alternative for anticancer drug development.
• Further research into PPI inhibitors could overcome limitations of current therapies.
• This strategy holds potential for improved cancer treatment outcomes.